Supreme Court: Stem Cells Not For Autism Treatment

The Supreme Court of India has issued a significant ruling, prohibiting the clinical use of stem cell therapy for Autism Spectrum Disorder (ASD). This decision arises from concerns about unproven and experimental therapies being offered to families seeking solutions for ASD, a complex neurodevelopmental condition.

The court emphasized that administering stem cell interventions for autism outside of regulated clinical trials constitutes medical malpractice. This reinforces the principle that patients cannot demand unproven treatments as a right, and consent is only valid if based on credible scientific information.

For individuals already receiving stem cell therapy, the Supreme Court directed the National Medical Commission and other health authorities to facilitate their transition into approved clinical trials. This measure ensures continued care while upholding ethical research standards and patient safety.

The judgment highlights that consent for medical treatment is invalidated if not grounded in adequate scientific evidence. Offering a choice between no treatment and an unproven therapy, particularly to vulnerable families, does not constitute valid informed consent, aligning with global ethical guidelines.

Doctors administering treatments lacking credible scientific evidence or recommended by authoritative bodies risk liability for medical negligence. The ruling underscores that medical practice must adhere to accepted professional standards and current scientific knowledge, especially concerning experimental interventions.